个人简介
王昕（https://www.x-mol.com/groups/wang_xin），香港中文大学医学院药理学博士，香港大学和美国得州大学医学院博士后，华东师范大学教授，博士生导师，荣获中国药理学会施维雅青年药理学家奖和刘昌孝人才奖励基金优秀青年科技工作者奖,主要研究方向为药物代谢及创新代谢模型构建。作为课题负责人承担国自然及省部级等课题13项，在国内外发表学术论文100余篇，其中以通讯作者或第一作者在国际著名学术期刊Nat Commun,Biochem Pharmacol,Pharmacol Res,Acta Pharm Sin B,Drug Metab Dispos,Toxicol Appl Pharmacol,Mol Pharmacol等发表SCI论文68篇，申请发明专利13项获授权8项，主编英文学术专著2部，参编学术专著5部，担任中国药理学会药物代谢专业委员会委员/青委副主委，中国毒理学会青年委员，药物毒理与安全性评价专业委员会委员，药物代谢朝阳论坛委员,上海药物代谢专业委员会委员，药学学报中英文期刊青年编委，为46个药理、植物医学、代谢及毒理学国际知名SCI学术期刊审稿，例如：Biochem Pharmcol, J Pharm Biomed Anal，Diabetes Obes Metab，J Nat Prod等，多次荣获国际药理学知名期刊J Pharm Biomed Anal，国际植物医学知名期刊Phytomedicine，J Ethnopharmacol及国际食品科学知名期刊J Funct Foods颁发的杰出贡献奖。
指导学生获奖
国家级
2023年 硕士生付田田 荣获研究生国家奖学金
2022年 硕士生徐媛 荣获研究生国家奖学金
2021年 硕士生刘洁 荣获研究生国家奖学金
2020年 本科生徐媛，罗函荣获第五届全国大学生生命科学创新创业大赛一等奖
2019年 张远金荣获中国毒理学会药物毒理与安全性评价学术大会青年优秀论文奖
2019年 硕士生程怡，尚旭阳获得研究生国家奖学金
2018年 覃璇荣获博士研究生国家奖学金
2018年 张远金荣获第十二届全国药物和化学异物代谢大会青年优秀论文奖
2017年 硕士生唐朔文获得研究生国家奖学金
2016年 博士生覃璇，陈昂分别荣获第二届药物代谢朝阳论坛---朝阳学子报告二，三等奖
2016年 博士生鲁健获得中国药理学会第十四次全国学术大会优秀壁报奖
2016年 硕士生赵军芳获得研究生国家奖学金
2015年 硕士生陈昂，覃璇获得研究生国家奖学金
2014年 硕士生汤玉，丁同贵获得研究生国家奖学金
2013年 硕士生孙敏获得首届研究生国家奖学金
省级
2024年 付田田获上海市优秀毕业生称号
2023年 张远金荣获第七届浦江DMPK论坛优秀青年学术报告奖
2023年 徐媛获上海市优秀毕业生称号
2019年 梁辰美子获上海市优秀毕业生称号
2019年 罗函，徐媛荣获上海大学生创新创业训练计划项目基金
2018年 鲁健荣获第五届浦江DMPK论坛优秀青年论文奖
2017年 赵军芳获上海市优秀毕业生称号
2015年 汤玉获上海市优秀毕业生称号
2014年 孙敏获上海市优秀毕业生称号
校级
2024年 沈奕飞获华东师范大学本科生优秀毕业论文
2023年 张燕芳获华东师大优秀硕士学位论文
2023年 徐媛荣获第32届十佳女大学生称号
2020年 尚旭阳，程怡荣获华东师范大学优秀毕业生称号
2016年 张远金获华东师范大学优秀毕业生称号
2016年 赵军芳获华东师范大学优秀学生称号
2016年 硕士生周小静获华东师范大学研究生科研创新基金
2015年 硕士生张远金获华东师范大学优秀研究生奖学金
2015年 硕士生陈昂获华东师范大学研究生科研创新基金
2014年 本科生张禾雨获华东师范大学本科生优秀毕业论文
主编书籍
1 Xin Wang (Editor),《Dextromethorphan: Pharmacology, Clinical Uses and Health Effects》，ISBN:978-1-63484-016-3，美国诺华科学出版社Nova Science Publishers, Inc. (2015)
2 Xin Wang (Editor),《CRISPR: Advances in Research and Applications》，ISBN:978-1-53612-946-5，美国诺华科学出版社Nova Science Publishers, Inc. (2017)
参编书籍
1 《分析药理学》P264-282，化学工业出版社（2024）
2 《基础与临床中药毒理学》P377-386，香港商务出版社（2009）
3 《Caffeine Consumption and Health》P33-50，美国诺华科学出版社Nova Science Publishers, Inc. (2012)
4 《Advances in Chemistry Research: Volume 15》P133-142, 美国诺华科学出版社Nova Science Publishers, Inc. (2012)
5 《Cytochrome P450 Enzymes: Biochemistry, Pharmacology and Health Implications》P51-86, 美国诺华科学出版社Nova Science Publishers, Inc. (2014)
发表论文
Huang S, Yao B, Guo Y, Chen X, Xu Y, Huang J, Liu J, Liang C, Zhang Y, Wang X*. Construction of cytochrome P450 3A and P-glycoprotein knockout rats with application in rivaroxaban-verapamil interactions. Biochemical Pharmacology 2024, 230: 116566. doi: https://doi.org/10.1016/j.bcp.2024.116566
Huang S, Xu Y, Guo Y, Zhang Y, Tang Y, Liang C, Gao L, Yao B, Wang X*. Aspirin increases estrogen levels in the placenta to prevent preeclampsia by regulating placental metabolism and transport function. Biochemical Pharmacology 2024, 230: 116561. doi: https://doi.org/10.1016/j.bcp.2024.116561
Huang S, Yao B, Guo Y, Zhang Y, Li H, Zhang Y, Liu S, Wang X*. Human trophoblast organoids for improved prediction of placental ABC transporter-mediated drug transport. Toxicology and Applied Pharmacology 2024, 492: 117112. doi: 10.1016/j.taap.2024.117112
Zhang Y, Huang J, Huang S, Liu J, Deng L, Liang C, Guo Y, Yao B, Wang X*. Construction and characterization of a humanized SLCO1B1 rat model with its application in evaluating the uptake of different statins. Acta Pharmaceutica Sinica B 2024, 14(4): 1592-1604. (APSB推荐论文：设计构建OATP1B1人源化大鼠模型用于研究他汀类药物的摄取转运）
Liu J, Lu J, Yao B, Zhang Y, Huang S, Chen X, Shen Y, Wang X*. Construction of humanized CYP1A2 rats using CRISPR/CRISPR-associated protein 9 to promote drug metabolism and pharmacokinetic research. Drug Metabolism and Disposition 2024, 52(1): 56-62. (Cover story)
Zhang Y, Yao B, Guo Y, Huang S, Liu J, Zhang Y, Liang C, Huang J, Tang Y, Wang X*. Sorafenib reduces the production of epoxyeicosatrienoic acids and leads to cardiac injury by inhibiting CYP2J in rats. Biochemical Pharmacology 2024, 223: 116169. doi: https://doi.org/10.1016/j.bcp.2024.116169
Shen Y, Liu J, Yao B, Zhang Y, Huang S, Liang C, Huang J, Tang Y, Wang X*. Non-alcoholic fatty liver disease changes the expression and activity of hepatic drug-metabolizing enzymes and transporters in rats. Toxicology Letters 2024, 396: 36-47.
Zhang Y, Gao J, Xu Y, Liu J, Huang S, Li G, Yao B, Sun Z, Wang X*. Investigation of cytochrome P450 inhibitory properties of deoxyshikonin, a bioactive compound from Lithospermum erythrorhizon Sieb. et Zucc. Phytotherapy Research 2024, 38: 4855-4864.
Chen X, Lu N, Huang S, Zhang Y, Liu Z, Wang X*. Assessment of doxorubicin toxicity using human cardiac organoids: A novel model for evaluating drug cardiotoxicity. Chemico-Biological Interactions 2023, 386: 110777.
Lu J, Shang X, Yao B, Sun D, Liu J, Zhang Y, Wang H, Shi J, Chen H, Shi T, Liu M, Wang X*. The role of CYP1A1/2 in cholesterol ester accumulation provides a new perspective for the treatment of hypercholesterolemia. Acta Pharmaceutica Sinica B 2023, 13(2): 648-661. doi: 10.1016/j.apsb.2022.08.005 (APSB推荐论文https://mp.weixin.qq.com/s/Iz3uOmKRPQSwmJAh9CxOoA）
Zhang Y, Lu J, Huang S, Zhang Y, Liu J, Xu Y, Yao B, Wang X*. CYP2J deficiency leads to cardiac injury and presents dual regulatory effects on cardiac function in rats. Toxicology and Applied Pharmacology 2023, 473: 116610.
Liu J, Shang X, Yao B, Zhang Y, Huang S, Guo Y, Wang X*. Design and construction of carboxylesterase 2c gene knockout rats by CRISPR/Cas9. Current Drug Metabolism 2023, 24(3): 190-199.
Fu T, Yao B, Guo Y, Zhang Y, Huang S, Wang X*. Establishment of LC–MS/MS method for quantifying chlorpromazine metabolites with application to its metabolism in liver and placenta microsomes. Journal of Pharmaceutical and Biomedical Analysis 2023, 233: 115457.
Liao J, Chen S, Hsiao S, Jiang Y, Yang Y, Zhang Y, Wang X, Lai Y, Bauer DE, Wu Y. Therapeutic adenine base editing of human hematopoietic stem cells. Nature Communications 2023, 14(1): 207.
Liu J, Yao B, Gao L, Zhang Y, Huang S, Wang X*. Emerging role of carboxylesterases in nonalcoholic fatty liver disease. Biochemical Pharmacology 2022, 205: 115250. doi: 10.1016/j.bcp.2022.115250
Zhang Y, Gao L, Yao B, Huang S, Zhang Y, Liu J, Liu Z, Wang X*. Role of epoxyeicosatrienoic acids in cardiovascular diseases and cardiotoxicity of drugs. Life Sciences 2022, 310: 121122. doi: 10.1016/j.lfs.2022.121122
Zhang Y, Zhang L, Xu P, Qin X, Wang P, Cheng Y, Yao B, Wang X*. Cytochrome P450 2E1 gene knockout or inhibition prevents obesity induced by high-fat diet via regulating energy expenditure. Biochemical Pharmacology 2022, 202:115160.
Xu Y, Lu J, Guo Y, Zhang Y, Liu J, Huang S, Zhang Y, Gao L*, Wang X*. Hypercholesterolemia reduces the expression and function of hepatic drug metabolizing enzymes and transporters in rats. Toxicology Letters 2022, 364:1-11. doi.org/10.1016/j.toxlet.2022.05.009
Yu J, Chen X, Zhang Y, Cui X, Zhang Z, Guo W, Wang D, Huang S, Chen Y, Hu Y, Zhao C, Qiu J, Li Y, Meng M, Guo M, Shen F, Zhang M, Zhou B, Gu X, Wang J, Wang X*, Ma X*, Xu L*. Antibiotic Azithromycin inhibits brown/beige fat functionality and promotes obesity in human and rodents. Theranostics 2022; 12(3): 1187-1203. doi:10.7150/thno.63067
Gao J, Zhang Y, Lei X, Xu Y, Sun Z, Wang X*. Risk assessment of the inhibition of hydroxygenkwanin on human and rat cytochrome P450 by cocktail method. Toxicol In Vitro 2022, 79:105281. doi: 10.1016/j.tiv.2021.105281.
Wang X, Fa J, Zhang Y, Huang S, Liu J, Gao J, Xing L, Liu Z, Wang X*. Evaluation of herb–drug interaction between Danshen and rivaroxaban in rat and human liver microsomes. Frontiers in Pharmacology 2022, 13: 950525.
Fu B, Liao J, Chen S, Li W, Wang Q, Hu J, Yang F, Hsiao S, Jiang Y, Wang L, Chen F, Zhang Y, Wang X, Li D, Liu M, Wu Y. CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric β0/β0 transfusion-dependent β-thalassemia. Nature Medicine 2022, 28(8):1573-1580.
Wang W, He J, Yang J, Zhang C, Cheng Z, Zhang Y, Zhang Q, Wang P, Tang S, Wang X, Liu M, Lu W, Zhang HK. Scaffold Hopping Strategy to Identify Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy. Journal of Medicinal Chemistry 2022, 65(11):7896-7917.
Jin Y, Liu Q, Chen P, Zhao S, Jiang W, Wang F, Li P, Zhang Y, Lu W, Zhong TP, Ma X, Wang X, Gartland A, Wang N, Shah KM, Zhang H, Cao X, Yang L, Liu M, Luo J. A novel prostaglandin E receptor 4 (EP4) small molecule antagonist induces articular cartilage regeneration. Cell Discovery 2022, 8(1): 24.
Xing Y, Guo W, Wu M, Xie J, Huang D, Hu P, Zhou M, Zhang L, Zhang Q, Wang P, Wang X, Wang G, Wu H, Zhou C, Chen Y, Liu M, Yi Z, Sun Z. An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo. Cancer Letters 2022, 529: 100-111.
Lu J, Liu J, Guo Y, Zhang Y, Xu Y, Wang X*. CRISPR-Cas9: A method for establishing rat models of drug metabolism and pharmacokinetics. Acta Pharmaceutica Sinica B 2021, 11(10): 2973-2982. doi.org/10.1016/j.apsb.2021.01.007
Xu Y, Lu J, Yao B, Zhang Y, Huang S, Liu J, Zhang Y, Guo Y, Wang X*. P-glycoprotein mediates the pharmacokinetic interaction of olanzapine with fluoxetine in rats.Toxicology and Applied Pharmacology 2021, 431: 115735. https://doi.org/10.1016/j.taap.2021.115735
Liu J, Shang X, Huang S, Xu Y, Lu J, Zhang Y, Liu Z, Wang X*. Construction and characterization of CRISPR/Cas9 knockout rat model of carboxylesterase 2a gene. Molecular Pharmacology 2021, 100(5): 480-490. DOI: https://doi.org/10.1124/molpharm.121.000357 (Editor choice paper)
Liu J, Cheng Y, Zhang Y, Huang S, Liu Z, Wang X*. Lactobacillus rhamnosus induces CYP3A and changes the pharmacokinetics of verapamil in rats. Toxicology Letters 2021, 352: 46-53. https://doi.org/10.1016/j.toxlet.2021.09.010
Qin X, Zhang Y, Lu J, Huang S, Liu Z, Wang X*. CYP3A deficiency alters bile acid homeostasis and leads to changes in hepatic susceptibility in rats. Toxicology and Applied Pharmacology 2021, 429: 115703. doi.org/10.1016/j.taap.2021.115703
Zhang Y, Huang S, Zhong W, Chen W, Yao B, Wang X*. 3D organoids derived from the small intestine: An emerging tool for drug transport research. Acta Pharmaceutica Sinica B 2021, 11(7): 1697-1707. doi.org/10.1016/j.apsb.2020.12.002
Zhang Y, Huang S, Liu J, Wang X*. Construction and application of innovation gene-edited rats and intestinal 3D organoids models in drug metabolism and pharmacokinetics. Chinese Journal of Clinical Pharmacology and Therapeutics 2021, 26(8): 914-922. (Cover story)
Huang S, Zhang Y, Zhang Y, Liu J, Liu Z, Wang X*. Establishment of LC-MS/MS method for determination of aloperine in rat plasma and its application in preclinical pharmacokinetics. Journal of Chromatography B 2021, 1173(2):122671. doi.org/10.1016/j.jchromb.2021.122671
Sun D, Lu J, Zhang Y, Liu J, Liu Z, Yao B, Guo Y, Wang X*. Characterization of a novel CYP1A2 knockout rat model constructed by CRISPR/Cas9. Drug Metabolism and Disposition 2021, 49(8): 638-647.
Chen A, Zhang Y, Sun D, Xu Y, Guo Y, Wang X*. Investigation of the content differences of arachidonic acid metabolites in a mouse model of breast cancer by using LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis 2021, 194: 113763.
Lu W, Yu W, He J, Liu W, Yang J, Lin X, Zhang Y, Wang X, Jiang W, Luo J, Zhang Q, Yang H, Peng S, Yi Z, Ren S, Chen J, Siwko S, Nussinov R, Cheng F, Zhang H, Liu M. Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer. EMBO Molecular Medicine 2021, 13(1): e12798.
Lu J, Chen A, Ma X, Shang X, Zhang Y, Guo Y, Liu M, Wang X*. Generation and Characterization of Cytochrome P450 2J3/10 CRISPR/Cas9 Knockout Rat Model. Drug Metabolism and Disposition 2020, 48(11): 1129-1136. doi: 10.1124/dmd.120.000114 (Cover story)
Ma X, Shang X, Qin X, Lu J, Liu M, Wang X*. Characterization of organic anion transporting polypeptide 1b2 knockout rats generated by CRISPR/Cas9: A novel model for drug transport and hyperbilirubinemia disease. Acta Pharmaceutica Sinica B 2020, 10(5): 850-860. doi:10.1016/j.apsb.2019.11.007
Luo H, Xu Y, Sun D, Cheng Y, Sun Z, Gao J, Zhang Y, Wang X*. Assessment of the inhibition risk of paris saponins, bioactive compounds from Paris polyphylla, on CYP and UGT enzymes via cocktail inhibition assays. Regulatory Toxicology and Pharmacology 2020, 113: 104637.doi:10.1016/j.yrtph.2020.104637
Lu J, Shang X, Zhong W, Xu Y, Shi R, Wang X*. New insights of CYP1A in endogenous metabolism：a focus on single nucleotide polymorphisms and diseases. Acta Pharmaceutica Sinica B 2020, 10: 91-104. doi:10.1016/j.apsb.2019.11.016
Yang JJ, Yu WW, Hu LL, Liu WJ, Lin XH, Wang W, Zhang Q, Wang PL, Tang SW, Wang X, Liu M, Lu W, Zhang HK. Discovery and Characterization of 1H-1,2,3-Triazole Derivatives as Novel Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy. Journal of Medicinal Chemistry 2020, 63(2): 569-590.
Ma X, Qin X, Shang X, Liu M, Wang X*. Organic anion transport polypeptide 1b2 selectively affects the pharmacokinetic interaction between paclitaxel and sorafenib in rats. Biochemical Pharmacology 2019, 169：113612. doi:10.1016/j.bcp.2019.08.014
Li Y, Meng Q, Yang M, Liu D, Hou X, Tang L, Wang X#, Lyu Y, Chen X, Liu K, Yu A, Zuo Z, Bi H. Current Trends in Drug Metabolism and Pharmacokinetics. Acta Pharmaceutica Sinica B 2019, 9: 1113-1144. doi:10.1016/j.apsb.2019.10.001
Qin X, Wang X*. Role of vitamin D receptor in the regulation of CYP3A gene expression. Acta Pharmaceutica Sinica B 2019, 9: 1087-1098. doi:10.1016/j.apsb.2019.03.005
Zhang L, Xu P, Cheng Y, Wang P, Ma X, Liu M, Wang X*, Xu F*. Diet-induced obese alters the expression and function of hepatic drug-metabolizing enzymes and transporters in rats. Biochemical Pharmacology 2019, 164: 368-376. doi:10.1016/j.bcp.2019.05.002
Liang C, Zhao J, Lu J, Zhang Y, Ma X, Shang X, Li Y, Ma X, Liu M, Wang X*. Development and characterization of MDR1 (Mdr1a/b) CRISPR/Cas9 knockout rat model. Drug Metabolism and Disposition 2019 Feb;47(2):71-79. doi: 10.1124/dmd.118.084277
Cheng Y, Tang S, Chen A, Zhang Y, Liu M, Wang X*. Evaluation of the inhibition risk of shikonin on human and rat UDP-glucuronosyltransferases (UGT) through the cocktail approach. Toxicology Letters 2019, 312: 214-221. doi: 10.1016/j.toxlet.2019.05.017
Zhang L, Liang C, Xu P, Liu M, Xu F*, Wang X*. Characterization of in vitro Mrp2 transporter model based on intestinal organoids. Regulatory Toxicology and Pharmacology 2019, 108: 104449. doi:10.1016/j.yrtph.2019.104449
Tang S, Ma X, Lu J, Zhang Y, Liu M, Wang X*. Preclinical toxicology and toxicokinetic evaluation of ailanthone, a natural product against castration-resistant prostate cancer, in mice. Fitoterapia 2019, 136: 104161. doi:10.1016/j.fitote.2019.04.016
Li Y, He Y, Shao T, Pei H, Guo W, Mi D, Krimm I, Zhang Y, Wang P, Wang X, Liu M, Yi Z, Chen Y. Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin. Journal of Medicinal Chemistry 2019, 62(10):4949-4966.
Su L, Li J, Zhou Z, Huang D, Zhang Y, Pei H, Guo W, Wu H, Wang X, Liu M, Yang CG, Chen Y. Design, synthesis and evaluation of hybrid of tetrahydrocarbazole with 2,4-diaminopyrimidine scaffold as antibacterial agents. European Journal of Medicinal Chemistry 2019, 162: 203-211. doi: 10.1016/j.ejmech.2018.11.016.
He Y, Peng S, Wang J, Chen H, Cong X, Chen A, Hu M, Qin M, Wu H, Gao S, Wang L, Wang X*, Yi Z*, Liu M*. Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer. Nature Communications 2016, 7: 13122.
Cancer: Antimalarial agent shows potential for prostate cancer treatment(Nature Communications)
A drug used for malaria could stop prostate cancer tumours growing
Prostate cancer NEWS: Deadly tumours could be treated with MALARIA drug
Wang P, Qin X, Liu M, Wang X*. The burgeoning role of cytochrome P450-mediated vitamin D metabolites against colorectal cancer. Pharmacological Research 2018, 133: 9-20. doi:10.1016/j.phrs.2018.04.022
Qin X, Wang X*. Quantification of nucleotides and their sugar conjugates in biological samples: Purposes, instruments and applications. Journal of Pharmaceutical and Biomedical Analysis 2018, 158: 280-287. doi:10.1016/j.jpba.2018.06.013 (The invited review)
Lu J, Liu D, Zhou X, Chen A, Jiang Z, Ye X, Liu M, Wang X*.Plant natural product plumbagin presents potent inhibitory effect on human cytochrome P450 2J2 enzyme. Phytomedicine 2018, 39: 137-145. doi: 10.1016/j.phymed.2017.12.026
Chen A, Zhou X, Cheng Y, Tang S, Liu M, Wang X*. Design and optimization of the cocktail assay for rapid assessment of the activity of UGT enzymes in human and rat liver microsomes. Toxicology Letters 2018, 295: 379-389. doi: 10.1016/j.toxlet.2018.07.021
Li J, Li L, Qin X, Degrace P, Demizieux L, Limbu S, Wang X, Zhang M, Li D, Du Z. Inhibited carnitine synthesis causes systemic alteration of nutrient metabolism in zebrafish. Frontiers in Physiology 2018, 9: 509. doi:10.3389/fphys.2018.00509
Zhang L, Zhao J, Liang C, Liu M, Xu F*, Wang X*. A novel biosensor based on intestinal 3D organoids for detecting the function of BCRP. Drug Delivery 2017, 24: 1453-1459. doi:10.1080/10717544.2017.1381199
Tang S, Chen A, Zhou X, Zeng L, Liu M, Wang X*. Assessment of the inhibition risk of shikonin on cytochrome P450 via cocktail inhibition assay. Toxicology Letters 2017, 281: 74-83. doi: 10.1016/j.toxlet.2017.09.014
Qin X, Lu J, Wang P, Xu P, Liu M, Wang X*. Cytochrome P450 3A selectively affects the pharmacokinetic interaction between erlotinib and docetaxel in rats. Biochemical Pharmacology 2017, 143: 129-139. doi:10.1016/j.bcp.2017.07.013
Lu J, Zhang Y, Sun M, Liu M, Wang X*. Comprehensive assessment of Cucurbitacin E related hepatotoxicity and drug-drug interactions involving CYP3A and P-glycoprotein. Phytomedicine 2017, 26: 1-10.
Lu J, Shao Y, Qin X, Liu D, Chen A, Li D*, Liu M*, Wang X*. CRISPR knockout rat cytochrome P450 3A1/2 model for advancing drug metabolism and pharmacokinetics research. Scientific Reports 2017, 7: 42922.
Li JM, Li LY, Qin X, Ning LJ, Lu DL, Li DL, Zhang ML, Wang X*, Du ZY*. Systemic regulation of L-carnitine in nutritional metabolism in zebrafish, Danio rerio. Scientific Reports 2017, 7: 40815.
Qin X, Chen A, Lu J, Zhang YJ, Liu MY, Wang X*. Evaluation of plasma stability and pharmacokinetics of parthenolide in rats with LC-MS/MS analysis. Acta Pharmaceutica Sinica 2017, 52: 609-614. doi:10.16438/j.0513-4870.2016-1006
Wang X*, Tang Y, Lu J, Shao Y, Qin X, Li Y, Wang L, Li D, Liu M. Characterization of novel cytochrome P450 2E1 knockout rat model generated by CRISPR/Cas9. Biochemical Pharmacology 2016, 105: 80-90.
Qin X, Liu M, Wang X*. New insights into the androgen biotransformation in prostate cancer: a regulatory network among androgen, androgen receptors and UGTs. Pharmacological Research 2016, 106: 114-22.
Zhao J, Zeng Z, Sun J, Zhang Y, Li D, Zhang X, Liu M, Wang X*. A Novel Model of P-Glycoprotein Inhibitor Screening Using Human Small Intestinal Organoids. Basic & Clinical Pharmacology & Toxicology 2017, 120: 250-255.
Chen A, Zhou X, Tang S, Liu M, Wang X*. Evaluation of the inhibition potential of plumbagin against cytochrome P450 using LC-MS/MS and cocktail approach. Scientific Reports 2016, 6: 28482.
Zhang Y, Zeng Z, Zhao J, Li D, Liu M, Wang X*. Measurement of Rhodamine 123 in Three-Dimensional Organoids: A Novel Model for P-Glycoprotein Inhibitor Screening. Basic & Clinical Pharmacology & Toxicology 2016, 119: 349-352.
Qin M, Peng S, Liu N, Hu M, He Y, Li G, Chen H, He Y, Chen A, Wang X, Liu M, Chen Y, Yi Z. LG308, a novel synthetic compound with anti-microtubule activity in prostate cancer cells, exerts effective antitumor activity. J Pharmacol Exp Ther 2015, 355: 473-483.
Lu J, Ding T, Qin X, Liu M, Wang X*. In vitro and in vivo evaluation of cucurbitacin E on rat hepatic CYP2C11 expression and activity using LC-MS/MS. Sci China Life Sci 2017, 60: 215-224. doi：10.1007/s11427-015-4911-7.
Zheng C, Zhou W, Wang T, You P, Zhao Y, Yang Y, Wang X, Luo J, Chen Y, Liu M, Chen H. A Novel TGR5 Activator WB403 Promotes GLP-1 Secretion and Preserves Pancreatic β-Cells in Type 2 Diabetic Mice. PLoS One 2015 Jul 24;10(7): e0134051. doi: 10.1371/journal.pone.0134051.
Chen A, Qin X, Lu J, Yi Z, Liu M, Wang X*. Development of a validated LC-MS/MS method for the determination of ailanthone in rat plasma with application to pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis 2015, 102: 514-518.
Sun M, Tang Y, Ding T, Liu M, Wang X*. Investigation of cytochrome P450 inhibitory properties of maslinic acid, a bioactive compound from Olea europaea L., and its structure-activity relationship. Phytomedicine 2015, 22: 56-65.
Ding T, Zhang Y, Chen A, Tang Y, Liu M, Wang X*. Effects of Cucurbitacin E, a Tetracyclic Triterpene Compound from Cucurbitaceae, on the Pharmacokinetics and Pharmacodynamics of Warfarin in Rats. Basic & Clinical Pharmacology & Toxicology 2015, 116: 385-389. DOI: 10.1111/bcpt.12329
Yang F, Zhang T, Wu H, Yang Y, Liu N, Chen A, Li Q, Li J, Qin L, Jiang B, Wang X, Pang X, Yi Z, Liu M, Chen Y. Design and Optimization of Novel Hydroxamate-Based Histone Deacetylase Inhibitors of Bis-Substituted Aromatic Amides Bearing Potent Activities against Tumor Growth and Metastasis. Journal of Medicinal Chemistry 2014, 57: 9357-9369. DOI: 10.1021/jm5012148
Chen A, Qin X, Tang Y, Liu M, Wang X*. Evaluation of enzyme inhibition kinetics in drug-drug interactions. Chemico-Biological Interactions 2014, 222: 133-134.
Lu J, Qin X, Liu M, Wang X*. A note on CYP2J2-mediated terfenadine hydroxylation in human liver microsomes. Food and Chemical Toxicology 2014, 71: 284-285.
Sun M, Tang Y, Ding T, Liu M, Wang X*. Inhibitory effects of celastrol on rat liver cytochrome P450 1A2, 2C11, 2D6, 2E1 and 3A2 activity. Fitoterapia 2014, 92: 1-8.
Wang X*, Yeung JH. Investigation of cytochrome P450 1A2 and 3A inhibitory properties of Danshen tincture. Phytomedicine 2012, 19: 348-354.
Wang X*, Yeung JH. Inhibitory effect of tanshinones on rat CYP3A2 and CYP2C11 activity and its structure-activity relationship. Fitoterapia 2011, 82: 539-545.
Wang X*, Yeung JH. Effects of Salvia miltiorrhiza extract on the liver CYP3A activity in humans and rats. Phytotherapy Research 2011, 25: 1653-1659.
Wang X, Nanovskaya TN, Zhan Y, Abdel-Rahman SM, Hankins GD, Ahmed MS. Pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis. Journal of Maternal-Fetal and Neonatal Medicine 2011, 24: 444-448.
Wang X*(Corresponding author), Yeung JH. Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats. Journal of Pharmacy and Pharmacology 2010, 62: 1077-1083.
Wang X, Zhan Y, Rytting E, Patrikeeva S, Nanovskaya T, Clark S, et al. Pharmacokinetics of famotidine during pregnancy and postpartum. Journal of Clinical Pharmacology 2010, 50: 1076.
Wang X, Cheung CM, Lee WY, Or PM, Yeung JH. Major tanshinones of Danshen (Salvia miltiorrhiza) exhibit different modes of inhibition on human CYP1A2, CYP2C9, CYP2E1 and CYP3A4 activities in vitro. Phytomedicine 2010, 17: 868-875.
Wang X, Lee WY, Zhou X, Or PM, Yeung JH. A pharmacodynamic– pharmacokinetic (PD–PK) study on the effects of Danshen (Salvia miltiorrhiza) on midazolam, a model CYP3A probe substrate, in the rat. Phytomedicine 2010, 17: 876-883.
Wang X, Lee WY, Or PM, Yeung JH. Pharmacokinetic interaction studies of tanshinones with tolbutamide, a model CYP2C11 probe substrate, using liver microsomes, primary hepatocytes and in vivo in the rat. Phytomedicine 2010, 17: 203-211.
Wang X, Lee WY, Or PM, Yeung JH. Effects of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on rat CYP1A2 expression and metabolism of model CYP1A2 probe substrates. Phytomedicine 2009, 16: 712-725.
授权专利：
1 发明人：王昕等。发明名称：一种检测肝微粒体中UGT酶活性的cocktail方法。专利号ZL201710045239.4， 授权日2020年7月14日，申请日2017年1月22日。
2 发明人：王昕等。发明名称：人小肠3D类器官研究P-糖蛋白模型的构建方法和应用。专利号ZL201610345283.2， 授权日2020年1月7日，申请日2016年5月23日。
3 发明人：王昕等。发明名称：Cyp基因敲除大鼠的培育方法及其肝微粒体的制备方法。专利号ZL201510131768.7， 授权日2019年9月26日，申请日2015年3月24日。
4 发明人：王昕等。发明名称：一种检测3D类器官中P-gp介导Rh123转运的方法及应用。专利号ZL201510617275.4，授权日2018年8月24日，申请日2015年9月24日。
5 发明人：王昕等。发明名称：用于检测转运的生物传感器及其应用。专利号ZL201810161920.X，授权日2021年4月9日，申请日2018年2月27日。
6 发明人：王昕等。发明名称：一种Mdr1a/1b双基因敲除的方法及应用。专利号ZL201710771262.1，授权日2022年7月8日，申请日2017年8月31日。
7 发明人：王昕等。Ces2基因敲除大鼠模型的构建方法和应用。专利号ZL202010533212.1
8 发明人：王昕等。细胞色素P450酶人源化大鼠模型及其构建方法和应用。专利号ZL202010358608.7
申请专利：
1 发明人：王昕等。一种重组人源CYP3A4/CPR/cyt b5蛋白共转染共表达的方法。 申请号CN201410842611.0
2 发明人：王昕等。一种小肠3D类器官研究BCRP介导药物转运模型的构建方法与应用。申请号CN201710320167.X
3 发明人：王昕等。一种高效表达人源CYP2J2重组酶的方法和应用。申请号CN201710531480.8
4 发明人：王昕等。一种Slco1b2基因敲除大鼠的培育方法及应用。申请号CN201811068044.2
5 发明人：王昕等。一种利用3D类器官评价药物肠毒性的检测方法。申请号CN201910028168.6
6 发明人：王昕等。一种滋养层类器官模型及其构建方法和应用。申请号CN202311486996.7
欢迎青年才俊加入我们ECNU DMPK GROUP！
本课题组一直从事生理活性物质的代谢转运及其调控疾病的机制研究，在国际上率先得到系列代谢酶及转运蛋白敲除大鼠，已取得多项国际领先的科研成果。课题组招收硕士，博士，同时招聘博士后，助理研究员和副研究员，欢迎青年才俊申请。
